HOPKINTON, Mass., Aug. 2, 2011 /PRNewswire/ — Caliper Life Sciences, Inc. (NASDAQ: CALP) today reported its financial results for the second quarter ended June 30, 2011. Second quarter revenue increased to $38.3 million, or 32%, from $29.1 million in the same period of 2010. Organic revenue, which excludes the effects of acquisitions, divestitures and currency changes, grew by 23% over the second quarter of 2010 (24% on a year-to-date basis). Caliper reported a second quarter net loss of $0.06 per share compared to net income per share of $0.18 in the same period of 2010, which resulted from the gain on the divestiture of Caliper’s former specialty products business. Caliper had second quarter non-GAAP adjusted earnings of $1.0 million, or $0.02 per diluted share compared to break-even non-GAAP adjusted earnings per share in the same period of 2010, as well as EBITDA of $2.7 million in the second quarter, which was an 84% improvement over the second quarter of 2010.
Please refer to the tables included under “Reconciliation of GAAP to Non-GAAP Financial Measures” for itemized reconciliations between GAAP and non-GAAP financial measures appearing in this release.
Among recent business highlights:
- Caliper announced on July 26 that its LabChip Dx instrument has achieved CE IVD registration which allows the LabChip Dx to be used to process clinical patient samples in Europe. The LabChip Dx currently runs tests from the Seeplex® menu of diagnostic assays from Seegene Inc. and is marketed outside of the United States through Seegene’s international distributor network.
- Caliper announced new collaborations during the second quarter for NGS sample preparation and quality control platforms with Roche Nimblegen, EdgeBio and The Genome Analysis Centre, involving the use of Caliper’s NGS platform solutions, including the Sciclone® NGS workstation and the LabChip GX and LabChip XT instruments.
- Caliper completed the integration and transfer of Cambridge Research & Instrumentation, Inc.’s (CRi) manufacturing operations from Woburn, Mass. to its Hopkinton, Mass. headquarters, resulting in closure of the Woburn facility in the second quarter. The shutdown occurred one quarter earlier than initially projected.
- Caliper hosted its 2011 annual Caliper Owners Group (COG 2011) meeting on May 17 and 18 at its Hopkinton headquarters. This thought-leadership conference brought together leaders in life sciences research, drug discovery, and diagnostics to discuss the technologies and discoveries that are transforming the detection and treatment of disease, and making personalized medicine a reality. More than 350 customers attended the event, which featured 45 presentations from researchers representing life sciences companies, universities and other institutions.
“We are pleased with our second quarter financial results and the strategic progress we made in the quarter,” commented Kevin Hrusovsky, President and CEO of Caliper Life Sciences. “We had a robust quarter in our Research business unit due to strong ongoing adoption of our NGS sample preparation solutions, molecular diagnostics penetration with the LabChip Dx, and continued LabChip GX adoption driven by biotherapeutic and vaccine development. In addition, our recently announced CE IVD approval opens up new market opportunities in Europe for the LabChip Dx, and enhances our clinical diagnostics long-term growth potential. We are particularly pleased that our strategic transformation designed to commercialize disruptive technologies for revolutionizing and personalizing medicine is gaining momentum and traction in all target markets,” added Hrusovsky.
Analysis of Second Quarter 2011 Results
- GAAP revenue increased 32% in the second quarter of 2011 compared to the same period in 2010. Non-GAAP revenues grew 37% in the second quarter of 2011 compared to the same period of 2010, comprised of 23% organic growth, 10% acquisition-driven growth and 4% favorable currency benefit. Non-GAAP revenue growth for each of Caliper’s three principal business units was as follows:
- Research revenue grew 52%, comprised of microfluidics (LabChip) and automation product line growth of 51% and 53%, respectively. Both LabChip and automation growth was driven by end market demand for Caliper’s analytical and preparative NGS sample preparation and quality control platforms. LabChip revenues also benefitted from increasing market adoption of Caliper’s LabChip Dx instrument for multiplex molecular diagnostic analysis, for which CE IVD approval was recently received, and an increase in microfluidics intellectual property license revenue.
- Imaging revenue grew 23% driven primarily by tissue imaging products added to Caliper’s imaging platform capabilities as a result of its acquisition of CRi in December 2010. In vivo imaging revenues were relatively flat quarter over quarter due primarily to some delayed funding situations in certain academic and commercial accounts, and to a lesser extent to the product mix sold during the quarter.
- Services (CDAS) revenue grew 82% primarily attributable to revenues from CDAS’ contract with the Environmental Protection Agency (“EPA”) under the EPA’s ToxCast(TM) screening program.
- Total gross margin was relatively flat at 52% compared to the second quarter of 2010 due to unfavorable changes in revenue and sales channel mix which partially offset the incremental contribution that overall higher revenues had upon gross margin.
- Operating expenses (research and development, and selling, general and administrative costs) increased 27% to $19.1 million, from $15.0 million in the same period in 2010. Approximately one-half of the increase was attributable to incremental operating expenses incurred as a result of the addition of CRi’s operations. The remainder of the expense increase resulted primarily from increased investment in sales and marketing efforts and increased legal expenses due to litigation which was ongoing during the second quarter.
- Caliper recorded a restructuring charge of approximately $1.3 million in the second quarter related to the closure of the CRi facility in Woburn, Mass. Caliper also recorded a charge of approximately $1.1 million, in addition to scheduled amortization, to write-off certain in-process research and development assets deemed to no longer have value.
2011 Guidance
Caliper is currently projecting 2011 full year GAAP revenue between $146 and $152 million. In addition, the Company estimates third quarter revenues in the range of $33 to $36 million. Caliper will provide further details on its business outlook during the conference call today.
Use of Non-GAAP Financial Measures
Caliper supplements its GAAP financial reporting with certain non-GAAP financial measures. Reconciliations of Caliper’s GAAP to non-GAAP revenue and earnings per share are provided at the end of this release under “Reconciliation of GAAP to Non-GAAP Financial Measures.”
Certain revenue growth percentages in this press release are derived from non-GAAP revenues which exclude the impact of revenue from product and services lines which were divested in the second quarter of 2010. Caliper believes that providing this additional information enhances investors’ understanding of the financial performance of the Company’s operations and increases the comparability of its current financial statements to prior periods.
Caliper will discuss its second quarter results in a conference call to be held today at 5:00 pm ET. Participants should call 888.680.0860 five to ten minutes prior to the call and use the participant passcode of 39159073. International callers can access the call by dialing 617.213.4852 and entering the same passcode. You may also pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=P8J9TBCRA.
A live webcast of the call can be accessed at www.earnings.com or on the Caliper website at www.caliperLS.com in the Events section of the Investor Relations page. A webcast replay of the call will remain available until Caliper’s earnings call for the third quarter of 2011.
Telephone replays of the conference call will be available approximately two hours after the completion of the call. To access a telephone playback of the proceedings from August 2 to August 9, dial 888.286.8010 and passcode 70172145. International callers can access the playback by dialing 617.801.6888 and using the same participant passcode.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper’s portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
The statements in this press release regarding future events, including Caliper’s 2011 full year and third quarter GAAP revenue projections, are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that Caliper’s expectations regarding demand for its products and services may not materialize if capital spending by Caliper’s customers declines, if customers do not purchase the recently acquired CRi products as rapidly as Caliper believes that they will, or if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its microfluidic and imaging systems and products. Further information on risks faced by Caliper are detailed under the caption “Risks Related To Our Business” in Caliper’s Annual Report on Form 10-K for the year ended December 31, 2010. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.
NOTE: Caliper, LabChip and Sciclone are registered trademarks of Caliper Life Sciences, Inc. CRi is a registered trademark of Cambridge Research & Instrumentation, Inc., a wholly owned subsidiary of Caliper Life Sciences, Inc. ToxCast is a trademark of the Environmental Protection Agency. Seeplex is a registered trademark of Seegene, Inc.
CALIPER LIFE SCIENCES, INC.
SELECTED FINANCIAL INFORMATION
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
Three Months
Ended
June 30,
--------
2011 2010
---- ----
Revenue:
Product revenue $26,711 $20,486
Service revenue 6,823 5,343
License fees and contract
revenue 4,807 3,221
Total revenue 38,341 29,050
Costs and expenses:
Cost of product revenue 13,602 10,101
Cost of service revenue 3,916 3,317
Cost of license revenue 971 521
Research and development 5,510 4,299
Selling, general and
administrative 13,542 10,745
Amortization of intangible
assets 2,503 1,226
Restructuring charges, net 1,399 603
Total costs and expenses 41,443 30,812
Operating loss (3,102) (1,762)
Interest expense, net (50) (72)
Gain on divestitures - 11,424
Other income (expense), net 91 (37)
Provision for income taxes (178) (316)
Net income (loss) $(3,239) $9,237
Net income (loss) per share,
basic $(0.06) $0.18
Net income (loss) per share,
diluted $(0.06) $0.18
Shares used in computing net
income (loss) per common
share, basic 52,417 50,070
Shares used in computing net
income (loss) per common
share, diluted 52,417 52,002
Six Months Ended
June 30,
--------
2011 2010
---- ----
Revenue:
Product revenue $51,653 $40,854
Service revenue 14,055 10,424
License fees and contract
revenue 8,453 6,424
Total revenue 74,161 57,702
Costs and expenses:
Cost of product revenue 26,497 20,396
Cost of service revenue 7,612 6,507
Cost of license revenue 1,616 926
Research and development 10,902 8,646
Selling, general and
administrative 27,262 21,604
Amortization of intangible
assets 3,944 2,480
Restructuring charges, net 2,263 634
Total costs and expenses 80,096 61,193
Operating loss (5,935) (3,491)
Interest expense, net (85) (202)
Gain on divestitures - 11,424
Other income (expense), net 403 (389)
Provision for income taxes (217) (323)
Net income (loss) $(5,834) $7,019
Net income (loss) per share,
basic $(0.11) $0.14
Net income (loss) per share,
diluted $(0.11) $0.14
Shares used in computing net
income (loss) per common
share, basic 52,236 49,776
Shares used in computing net
income (loss) per common
share, diluted 52,236 51,812
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
Non-GAAP Earnings and Earnings per Share (see explanation of
adjustments below)(in thousands except per share data)
Three Months
Ended
June 30,
--------
2011 2010
---- ----
GAAP income (loss) $(3,239) $9,237
GAAP EPS - Basic $(0.06) $0.18
Adjustments:
Acquisition related intangible amortization
(1) $2,503 $1,226
Restructuring and severance costs (2) 1,399 603
Purchase accounting and acquisition related
costs (3) 226 -
Gain on divestiture of product lines (4) - (11,424)
Taxes related to divestiture gain(4) - 300
--- ---
Total Adjustments $4,128 $(9,295)
Per share effect of adjustments, basic $0.08 $(0.19)
Non-GAAP adjusted earnings (loss) $889 $(58)
Non-GAAP adjusted earnings (loss) per
share, basic and diluted $0.02 $(0.00)
Shares used in computing non-GAAP adjusted
earnings (loss) per share, basic 52,417 50,070
Shares used in computing non-GAAP adjusted
earnings (loss) per share, diluted 56,606 52,002
Six Months Ended
June 30,
--------
2011 2010
---- ----
GAAP income (loss) $(5,834) $7,019
GAAP EPS - Basic $(0.11) $0.14
Adjustments:
Acquisition related intangible
amortization (1) $3,944 $2,480
Restructuring and severance costs
(2) 2,263 634
Purchase accounting and acquisition
related costs (3) 844 -
Gain on divestiture of product lines
(4) - (11,424)
Taxes related to divestiture gain(4) - 300
--- ---
Total Adjustments $7,051 $(8,010)
Per share effect of adjustments,
basic $0.13 $(0.16)
Non-GAAP adjusted earnings (loss) $1,217 $(991)
Non-GAAP adjusted earnings (loss)
per share, basic and diluted $0.02 $(0.02)
Shares used in computing non-GAAP
adjusted earnings (loss) per share,
basic 52,236 49,776
Shares used in computing non-GAAP
adjusted earnings (loss) per share,
diluted 56,097 51,812
We use the term “adjusted earnings per share” or “adjusted EPS” to refer to GAAP earnings per share excluding amortization of intangible assets, impairment charges and restructuring and severance costs. Adjusted earnings per share is calculated by subtracting the total per share effect of these adjustments from GAAP EPS.
The adjustments are as follows:
(1) We exclude amortization of intangible assets from this measure because intangible asset amortization charges do not represent what our management believes are the costs of developing, producing, supporting and selling our products and the costs to support our internal operating structure.
(2) We exclude restructuring and severance costs from this measure because they tend to occur as a result of specific events such as acquisitions, divestitures, repositioning our business or other unusual events that could make comparisons of long-range trends difficult and are not reflective of our internal investments and the costs to support our operating structure.
(3) We exclude purchase accounting adjustments and acquisition related costs from this measure because they occur as a result of specific events and are not reflective of our internal investments and the costs to support our operating structure. The costs within 2011 relate to CRi and consist of purchase accounting adjustments to value acquired inventory at fair value as well as a charge to terminate a CRi distributor relationship.
(4) We exclude the net gain related to divestitures of product and service lines from this measure because they tend to occur as a result of specific events and also do not represent what our management and our investors believe are the costs of developing, producing, supporting and selling our products and the costs to support our internal operating structure.
Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited, continued)
Non-GAAP Revenues (in thousands) for the Three Months Ended June 30, 2011
GAAP
----
2011 2010 Non-GAAP
---- ---- --------
Adjustments
(1)
------------
2010
----
Imaging $18,206 $14,826 $ -
LabChip 11,183 7,412 -
Automation 7,135 5,811 (1,152)
----- ----- ------
Research 18,318 13,223 (1,152)
Services
(CDAS) 1,817 1,001 -
----- ----- ---
Total
revenue $38,341 $29,050 $(1,152)
======= ======= =======
Non- Non-
GAAP GAAP GAAP
---- ---- ----
%
2010 Chg. % Chg.
---- ----- ------
Imaging $14,826 23% 23%
LabChip 7,412 51% 51%
Automation 4,659 23% 53%
----- --- ---
Research 12,071 39% 52%
Services
(CDAS) 1,001 82% 82%
-----
Total
revenue $27,898 32% 37%
=======
Non-GAAP Revenues (in thousands) for the Six Months Ended June 30, 2011
GAAP
----
2011 2010 Non-GAAP
---- ---- --------
Adjustments
(1)
------------
2010
----
Imaging $37,607 $28,291 $ -
LabChip 20,013 14,182 -
Automation 12,464 13,060 (3,610)
------ ------ ------
Research 32,477 27,242 (3,610)
Services
(CDAS) 4,077 2,169 -
----- ----- ---
Total
revenue $74,161 $57,702 $(3,610)
======= ======= =======
Non- Non-
GAAP GAAP GAAP
---- ---- ----
%
2010 Chg. % Chg.
---- ----- ------
Imaging $28,291 33% 33%
LabChip 14,182 41% 41%
Automation 9,450 (5)% 32%
----- --- ---
Research 23,632 19% 37%
Services
(CDAS) 2,169 88% 88%
-----
Total
revenue $54,092 29% 37%
=======
For purposes of comparing growth rates for each of the three
principal product and service groups within of our business, the
above non-GAAP table reconciliations exclude revenues related to
(1) the TurboVap and RapidTrace product lines divested in May 2010.
Currency effects contributed to the above Research growth rates by
7% and 4% and the above Imaging growth rates by 3% and 2% during
(2) the three and six months ended June 30, 2011, respectively.
EBITDA (in thousands)
We use the term “EBITDA” to refer to GAAP earnings excluding interest, depreciation, amortization, non-cash stock compensation and other special items (e.g., restructuring charges). The following is a reconciliation of this Non-GAAP measure:
Three Months
Ended Six Months Ended
June 30, June 30,
-------- --------
2011 2010 2011 2010
---- ---- ---- ----
GAAP Operating
Loss $(3,102) $(1,762) $(5,935) $(3,491)
Depreciation and
amortization 3,169 1,812 5,265 3,708
Non-cash stock
compensation 959 790 1,948 1,802
Purchase
accounting and
acquisition
related costs 226 - 844 -
Restructuring and
severance charges 1,399 603 2,263 634
----- --- ----- ---
EBITDA (Non-GAAP) $2,651 $1,443 $4,385 $2,653
====== ====== ====== ======
CALIPER LIFE SCIENCES, INC.
SELECTED FINANCIAL INFORMATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
June December
30, 31,
2011 2010
---- ----
(unaudited) *
Assets
Current assets:
Cash, cash equivalents and
marketable securities $34,330 $34,846
Accounts receivable, net 25,939 26,544
Inventories 15,358 14,004
Other current assets 3,863 2,916
----- -----
Total current assets 79,490 78,310
Property and equipment, net 9,810 9,765
Intangible assets, net 23,853 27,797
Goodwill 27,958 27,958
Other assets 631 592
--- ---
Total assets $141,742 $144,422
======== ========
Liabilities and
stockholders' equity
Current liabilities $42,099 $42,404
Other long-term obligations 11,661 11,330
Stockholders' equity 87,982 90,688
------ ------
Total liabilities and
stockholders' equity $141,742 $144,422
*Note: Derived from audited financial statements for the year ended
December 31, 2010.
SOURCE Caliper Life Sciences, Inc.
Comments